Roche Holding (RHHBY)
(Delayed Data from OTC)
$40.71 USD
-0.01 (-0.02%)
Updated Aug 2, 2024 04:00 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RHHBY 40.71 -0.01(-0.02%)
Will RHHBY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RHHBY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RHHBY
Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues
Regeneron (REGN) Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales
RHHBY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dr. Reddy's (RDY) Q1 Earnings Miss Estimates, Revenues Beat
Affimed (AFMD) to Report Q2 Earnings: What's in the Cards?
Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?
Other News for RHHBY
Regeneron price target raised to $805 from $720 at BofA
REGENXBIO releases new data on DMD drug ahead of earnings
Roche price target raised by CHF 10 at JPMorgan
Roche's Vabysmo gains indication in Europe for retinal vein occlusion
Truist healthcare analyst holds an analyst/industry conference call